Phenominer Database Results (132 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Formula Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Clinical Measurement Notes Record ID Study ID
SS.ZUC-Leprfa+/+/Slc heart ventricle septal wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 10 0.18 cm 0.0 0.01 echocardiography 0.0 0 101784 2641
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. inguinal fat pad mass male 91 days 8 195.63 mg/mm 7.15 20.22 post excision weight measurement 0.0 0 if/tl 101779 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle end-diastolic diameter control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 8 8.09 mm 0.22 0.62 echocardiography 0.0 0 101787 2641
SS.ZUC-Leprfa+/+/Slc calculated heart left ventricle weight control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 8 948.71 mg 51.33 145.18 echocardiography 0.0 0 101795 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 9 0.2 g/cm 0.01 0.02 post excision weight measurement 0.0 ovariectomy 42 days lv/tl 101695 2622
SS.ZUC-Leprfa+/+/Slc systolic blood pressure bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. arterial blood pressure trait female 91 days 9 undefined 138.0 mmHg 1.0 3.0 tail cuff plethysmography 0.0 ovariectomy 42 days 101669 2622
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart mass female 91 days 9 0.26 g/cm 0.01 0.02 post excision weight measurement 0.0 ovariectomy 42 days 101681 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle relative wall thickness bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 9 44.0 % 2.0 6.0 echocardiography 0.0 ovariectomy 42 days 101727 2622
SS.ZUC-Leprfa+/+/Slc heart isovolumetric relaxation time bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart muscle relaxation trait female 91 days 9 24.8 ms 1.8 5.4 echocardiography 0.0 ovariectomy 42 days 101735 2622
SS.ZUC-Leprfa+/+/Slc E/A wave ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 10 1.72 null 0.06 0.19 echocardiography 0.0 0 101814 2641
SS.ZUC-Leprfa+/+/Slc E wave deceleration time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 10 38.2 ms 1.45 4.59 echocardiography 0.0 0 101818 2641
SS.ZUC-Leprfa+/+/Slc serum triglyceride level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood triglyceride amount male 91 days 10 87.0 mg/dl 4.08 12.9 serum triglyceride analysis 0.0 0 101850 2641
SS.ZUC-Leprfa+/+/Slc creatinine clearance to total kidney weight ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 8 0.48 ml/min/g 0.02 0.06 serum creatinine analysis 0.0 0 101881 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left ventricle mass male 126 days 6 0.24 g/cm 0.01 0.02 post excision weight measurement 0.0 0 lv/tl 101895 2642
SS.ZUC-Leprfa+/+/Slc heart left atrium weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left atrium mass male 126 days 6 2.06 mg/mm 0.23 0.56 post excision weight measurement 0.0 0 a/tl 101899 2642
SS.ZUC-Leprfa+/+/Slc liver weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. liver mass male 126 days 6 312.19 mg/mm 25.29 61.95 post excision weight measurement 0.0 0 liv/tl 101903 2642
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. inguinal fat pad mass male 126 days 6 158.77 mg/mm 27.34 66.97 post excision weight measurement 0.0 0 if/tl 101907 2642
SS.ZUC-Leprfa+/+/Slc ratio of survivors of metabolic syndrome to total study population during a period of time control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. total life span male 126 days 6 100.0 % necropsy 0.0 0 ratio of survivors of metabolic syndrome to total study population during a period of time (CMO:0003803) 101909 2642
SS.ZUC-Leprfa+/+/Slc creatinine clearance to body weight ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 10 0.39 ml/min/100g 0.04 0.13 serum creatinine analysis 0.0 0 101878 2641
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. inguinal fat pad mass female 91 days 9 32.0 mg/mm 3.0 9.0 post excision weight measurement 0.0 ovariectomy 42 days sf/tl 101703 2622
SS.ZUC-Leprfa+/+/Slc heart ventricle septal wall thickness bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 12 0.15 cm 0.0 0.01 echocardiography 0.0 ovariectomy 42 days 101708 2622
SS.ZUC-Leprfa+/+/Slc liver weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. liver mass male 91 days 10 296.35 mg/mm 14.18 44.84 post excision weight measurement 0.0 0 liv/tl 101764 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle relative wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 10 45.0 % 2.0 6.32 echocardiography 0.0 0 101802 2641
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart mass male 91 days 8 0.32 g/cm 0.01 0.0 post excision weight measurement 0.0 0 101755 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle posterior wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle posterior wall thickness male 91 days 8 1.56 mm 0.09 0.25 echocardiography 0.0 0 101791 2641
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. inguinal fat pad mass female 91 days 12 19.0 mg/mm 1.0 3.46 post excision weight measurement 0.0 ovariectomy 42 days sf/tl 101704 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle posterior wall thickness bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle posterior wall thickness female 91 days 12 1.4 mm 0.02 0.07 echocardiography 0.0 ovariectomy 42 days 101712 2622
SS.ZUC-Leprfa+/+/Slc calculated heart left ventricle weight bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 12 589.0 mg 31.0 107.39 echocardiography 0.0 ovariectomy 42 days 101724 2622
SS.ZUC-Leprfa+/+/Slc E wave deceleration time bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 12 53.6 ms 1.4 4.85 echocardiography 0.0 ovariectomy 42 days 101732 2622
SS.ZUC-Leprfa+/+/Slc left ventricular end-diastolic blood pressure bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 12 4.03 mmHg 0.28 0.97 vascular transducer tipped catheter 0.0 ovariectomy 42 days 101744 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 10 0.24 g/cm 0.01 0.02 post excision weight measurement 0.0 0 lv/tl 101760 2641
SS.ZUC-Leprfa+/+/Slc liver weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. liver mass male 91 days 8 283.3 mg/mm 9.54 26.98 post excision weight measurement 0.0 0 liv/tl 101763 2641
SS.ZUC-Leprfa+/+/Slc pancreas weight to tibia length control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. pancreas mass male 91 days 8 42.2 mg/mm 3.86 10.92 post excision weight measurement 0.0 0 p/tl 101833 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle fractional shortening control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 8 32.62 % 1.67 4.72 echocardiography 0.0 0 101805 2641
SS.ZUC-Leprfa+/+/Slc serum low density lipoprotein cholesterol level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood LDL cholesterol amount male 126 days 6 24.0 mg/dl 2.94 7.2 serum low-density lipoprotein-cholesterol measurement test 0.0 0 101921 2642
SS.ZUC-Leprfa+/+/Slc serum low density lipoprotein cholesterol to high density lipoprotein cholesterol ratio fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood cholesterol amount male 126 days 6 0.89 null 0.09 0.22 serum high-density lipoprotein-cholesterol measurement test 0.0 0 ldl/hdl 101925 2642
SS.ZUC-Leprfa+/+/Slc heart left ventricle fractional shortening everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 10 35.33 % 1.87 5.91 echocardiography 0.0 0 101806 2641
SS.ZUC-Leprfa+/+/Slc heart isovolumetric relaxation time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart muscle relaxation trait male 91 days 10 31.43 ms 1.47 4.65 echocardiography 0.0 0 101822 2641
SS.ZUC-Leprfa+/+/Slc blood high density lipoprotein cholesterol level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood HDL cholesterol amount male 91 days 8 13.05 mg/dl 2.54 7.18 blood cholesterol analysis 0.0 0 101841 2641
SS.ZUC-Leprfa+/+/Slc blood aspartate aminotransferase activity level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood aspartate transaminase amount male 91 days 10 59.0 U/l 7.42 23.46 automated blood analysis 0.0 0 101858 2641
SS.ZUC-Leprfa+/+/Slc systolic blood pressure control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. arterial blood pressure trait male 126 days 6 137.7 mmHg 3.04 7.45 tail cuff plethysmography 0.0 0 101889 2642
SS.ZUC-Leprfa+/+/Slc both kidneys wet weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. kidney mass male 126 days 6 0.78 g/cm 0.06 0.16 post excision weight measurement 0.0 0 101901 2642
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 8 0.24 g/cm 0.01 0.02 post excision weight measurement 0.0 0 lv/tl 101759 2641
SS.ZUC-Leprfa+/+/Slc urine protein level control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. total urine protein amount male 126 days 6 336.29 mg/d 19.58 47.96 urine protein analysis 0.0 0 101935 2642
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart mass male 91 days 10 0.34 g/cm 0.01 0.0 post excision weight measurement 0.0 0 101756 2641
SS.ZUC-Leprfa+/+/Slc single kidney weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. kidney mass male 91 days 10 29.2 g/cm 1.03 3.26 post excision weight measurement 0.0 0 101768 2641
SS.ZUC-Leprfa+/+/Slc epididymal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. epididymal fat pad mass male 91 days 8 1.22 g/cm 0.07 0.21 post excision weight measurement 0.0 0 ef/tl 101775 2641
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. retroperitoneal fat pad mass female 91 days 9 105.0 mg/mm 9.0 27.0 post excision weight measurement 0.0 ovariectomy 42 days vf/tl 101699 2622
SS.ZUC-Leprfa+/+/Slc body weight bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. body mass female 91 days 12 220.0 g 4.0 13.86 body weighing method 0.0 ovariectomy 42 days 101662 2622
SS.ZUC-Leprfa+/+/Slc tibia straight segment length bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. tibia length female 91 days 9 35.8 mm 0.4 1.2 body length measuring method 0.0 ovariectomy 42 days 101665 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle fractional shortening bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 9 39.8 % 2.5 7.5 echocardiography 0.0 ovariectomy 42 days 101719 2622
SS.ZUC-Leprfa+/+/Slc E wave deceleration time bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 9 35.4 ms 1.2 3.6 echocardiography 0.0 ovariectomy 42 days 101731 2622
SS.ZUC-Leprfa+/+/Slc myocardial performance index bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 9 0.44 null 0.01 0.03 echocardiography 0.0 ovariectomy 42 days 101739 2622
SS.ZUC-Leprfa+/+/Slc E wave deceleration time control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 8 33.89 ms 1.4 3.96 echocardiography 0.0 0 101817 2641
SS.ZUC-Leprfa+/+/Slc serum total cholesterol level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood cholesterol amount male 126 days 6 116.25 mg/dl 11.59 28.39 serum total cholesterol measurement test 0.0 0 101919 2642
SS.ZUC-Leprfa+/+/Slc serum alanine aminotransferase activity level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood alanine transaminase amount male 126 days 6 24.67 U/l 0.88 2.16 automated blood analysis 0.0 0 101929 2642
SS.ZUC-Leprfa+/+/Slc serum urea nitrogen level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood urea nitrogen amount male 126 days 6 19.98 mg/dl 1.86 4.56 serum urea nitrogen analysis 0.0 0 101931 2642
SS.ZUC-Leprfa+/+/Slc serum creatinine level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood creatinine amount male 126 days 6 0.32 mg/dl 0.03 0.07 serum creatinine analysis 0.0 0 101933 2642
SS.ZUC-Leprfa+/+/Slc ejection fraction control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. cardiac output trait male 91 days 8 69.1 % 2.22 6.28 echocardiography 0.0 0 101809 2641
SS.ZUC-Leprfa+/+/Slc blood alanine aminotransferase activity level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood alanine transaminase amount male 91 days 8 20.5 U/l 0.5 1.41 automated blood analysis 0.0 0 101861 2641
SS.ZUC-Leprfa+/+/Slc urine total protein level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. total urine protein amount male 91 days 8 7.51 mg/ml 0.17 0.49 urine protein analysis 0.0 0 101869 2641
SS.ZUC-Leprfa+/+/Slc creatinine clearance to total kidney weight ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 10 0.47 ml/min/g 0.05 0.16 serum creatinine analysis 0.0 0 101882 2641
SS.ZUC-Leprfa+/+/Slc body weight control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. body mass male 126 days 6 443.75 g 21.62 52.96 body weighing method 0.0 0 101885 2642
SS.ZUC-Leprfa+/+/Slc E/A wave ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 8 - 1.95 null 0.09 0.25 echocardiography 0.0 0 e/a 101813 2641
SS.ZUC-Leprfa+/+/Slc serum free fatty acids level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood free fatty acid amount male 91 days 10 15.09 mmol/l 1.17 3.69 serum free fatty acid analysis 0.0 0 **suspected wrong units in paper(mg/dl) 101854 2641
SS.ZUC-Leprfa+/+/Slc urine total protein level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. total urine protein amount male 91 days 10 4.79 mg/ml 1.47 4.64 urine protein analysis 0.0 0 101870 2641
SS.ZUC-Leprfa+/+/Slc single kidney weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. kidney mass male 91 days 8 30.3 g/cm 1.57 4.44 post excision weight measurement 0.0 0 k/tl 101767 2641
SS.ZUC-Leprfa+/+/Slc time constant of left ventricular pressure decay bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 12 46.8 ms 2.9 10.05 echocardiography 0.0 ovariectomy 42 days 101748 2622
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. retroperitoneal fat pad mass male 91 days 8 111.71 mg/mm 5.99 16.94 post excision weight measurement 0.0 0 rf/tl 101771 2641
SS.ZUC-Leprfa+/+/Slc epididymal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. epididymal fat pad mass male 91 days 10 1.29 g/cm 0.03 0.11 post excision weight measurement 0.0 0 ef/tl 101776 2641
SS.ZUC-Leprfa+/+/Slc heart ventricle septal wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 8 0.16 cm 0.01 0.01 echocardiography 0.0 0 101783 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle end-diastolic diameter everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 10 7.65 mm 0.12 0.38 echocardiography 0.0 0 101788 2641
SS.ZUC-Leprfa+/+/Slc calculated heart left ventricle weight everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 10 962.28 mg 30.76 97.27 echocardiography 0.0 0 101796 2641
SS.ZUC-Leprfa+/+/Slc heart ventricle septal wall thickness bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 9 0.16 cm 0.0 0.01 echocardiography 0.0 ovariectomy 42 days 101707 2622
SS.ZUC-Leprfa+/+/Slc body weight bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. body mass female 91 days 9 294.0 g 6.0 18.0 body weighing method 0.0 ovariectomy 42 days 101661 2622
SS.ZUC-Leprfa+/+/Slc systolic blood pressure bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. arterial blood pressure trait female 91 days 12 undefined 141.0 mmHg 4.0 13.86 tail cuff plethysmography 0.0 ovariectomy 42 days 101670 2622
SS.ZUC-Leprfa+/+/Slc heart rate bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 9 380.0 beats/min 8.0 24.0 tail cuff plethysmography 0.0 ovariectomy 42 days 101673 2622
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart mass female 91 days 12 0.23 g/cm 0.0 0.01 post excision weight measurement 0.0 ovariectomy 42 days 101682 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle posterior wall thickness bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle posterior wall thickness female 91 days 9 1.5 mm 0.02 0.06 echocardiography 0.0 ovariectomy 42 days 101711 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle end-diastolic diameter bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 9 7.21 mm 0.21 0.63 echocardiography 0.0 ovariectomy 42 days 101715 2622
SS.ZUC-Leprfa+/+/Slc calculated heart left ventricle weight bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 9 764.0 mg 27.0 81.0 echocardiography 0.0 ovariectomy 42 days 101723 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle relative wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 8 39.0 % 2.0 5.66 echocardiography 0.0 0 101801 2641
SS.ZUC-Leprfa+/+/Slc pancreas weight to tibia length everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. pancreas mass male 91 days 10 39.44 mg/mm 1.95 6.17 post excision weight measurement 0.0 0 p/tl 101834 2641
SS.ZUC-Leprfa+/+/Slc serum leptin level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood leptin amount male 126 days 6 1.67 ng/ml 0.37 0.91 enzyme linked immunosorbent assay 0.0 0 101911 2642
SS.ZUC-Leprfa+/+/Slc serum glucose level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood glucose amount male 126 days 6 124.5 mg/dl 6.4 15.68 serum glucose analysis 0.0 0 101913 2642
SS.ZUC-Leprfa+/+/Slc serum high density lipoprotein cholesterol level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood HDL cholesterol amount male 126 days 6 26.75 mg/dl 1.11 2.72 serum high-density lipoprotein-cholesterol measurement test 0.0 0 101923 2642
SS.ZUC-Leprfa+/+/Slc heart isovolumetric relaxation time control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart muscle relaxation trait male 91 days 8 24.22 ms 2.42 6.84 echocardiography 0.0 0 101821 2641
SS.ZUC-Leprfa+/+/Slc time constant of left ventricular pressure decay control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 8 27.47 ms 0.82 2.32 echocardiography 0.0 0 101825 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 4 0.56 mmHg/mm 0.04 0.08 echocardiography 0.0 0 lvedp/lvdd 101829 2641
SS.ZUC-Leprfa+/+/Slc serum free fatty acids level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood free fatty acid amount male 91 days 8 15.07 mmol/l 0.66 1.86 serum free fatty acid analysis 0.0 0 **suspected wrong units in paper(mg/dl) 101853 2641
SS.ZUC-Leprfa+/+/Slc blood low density lipoprotein cholesterol level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood LDL cholesterol amount male 91 days 8 25.0 mg/dl 6.0 16.97 blood cholesterol analysis 0.0 0 101845 2641
SS.ZUC-Leprfa+/+/Slc serum triglyceride level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood triglyceride amount male 91 days 8 54.5 mg/dl 9.5 26.87 serum triglyceride analysis 0.0 0 101849 2641
SS.ZUC-Leprfa+/+/Slc serum creatinine level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood creatinine amount male 91 days 8 0.35 mg/dl 0.01 0.03 serum creatinine analysis 0.0 0 101873 2641
SS.ZUC-Leprfa+/+/Slc serum creatinine level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood creatinine amount male 91 days 10 0.34 mg/dl 0.01 0.03 serum creatinine analysis 0.0 0 101874 2641
SS.ZUC-Leprfa+/+/Slc heart rate control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart pumping trait male 126 days 6 417.32 beats/min 13.71 33.58 tail cuff plethysmography 0.0 0 101891 2642
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. retroperitoneal fat pad mass male 126 days 6 178.02 mg/mm 31.55 77.28 post excision weight measurement 0.0 0 rf/tl 101905 2642
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. retroperitoneal fat pad mass male 91 days 10 113.78 mg/mm 2.71 8.57 post excision weight measurement 0.0 0 rf/tl 101772 2641
SS.ZUC-Leprfa+/+/Slc inguinal fat pad weight to tibia length ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. inguinal fat pad mass male 91 days 10 196.56 mg/mm 8.21 25.96 post excision weight measurement 0.0 0 if/tl 101780 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 9 0.32 mmHg/mm 0.02 0.06 echocardiography 0.0 ovariectomy 42 days 101751 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 5 0.6 mmHg/mm 0.05 0.11 echocardiography 0.0 0 lvedp/lvdd 101830 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle posterior wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle posterior wall thickness male 91 days 10 1.7 mm 0.06 0.19 echocardiography 0.0 0 101792 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 12 0.18 g/cm 0.0 0.01 post excision weight measurement 0.0 ovariectomy 42 days lv/tl 101696 2622
SS.ZUC-Leprfa+/+/Slc tibia straight segment length bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. tibia length female 91 days 12 33.6 mm 0.2 0.69 body length measuring method 0.0 ovariectomy 42 days 101666 2622
SS.ZUC-Leprfa+/+/Slc heart rate bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 12 392.0 beats/min 5.0 17.32 tail cuff plethysmography 0.0 ovariectomy 42 days 101674 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle end-diastolic diameter bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 12 6.5 mm 0.17 0.59 echocardiography 0.0 ovariectomy 42 days 101716 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle fractional shortening bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 12 55.2 % 1.9 6.58 echocardiography 0.0 ovariectomy 42 days 101720 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricle relative wall thickness bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 12 45.0 % 1.0 3.46 echocardiography 0.0 ovariectomy 42 days 101728 2622
SS.ZUC-Leprfa+/+/Slc heart isovolumetric relaxation time bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart muscle relaxation trait female 91 days 12 39.0 ms 1.0 3.46 echocardiography 0.0 ovariectomy 42 days 101736 2622
SS.ZUC-Leprfa+/+/Slc left ventricular end-diastolic blood pressure bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 9 2.27 mmHg 0.11 0.33 vascular transducer tipped catheter 0.0 ovariectomy 42 days 101743 2622
SS.ZUC-Leprfa+/+/Slc time constant of left ventricular pressure decay bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 9 36.2 ms 0.5 1.5 echocardiography 0.0 ovariectomy 42 days 101747 2622
SS.ZUC-Leprfa+/+/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 12 0.63 mmHg/mm 0.05 0.17 echocardiography 0.0 ovariectomy 42 days 101752 2622
SS.ZUC-Leprfa+/+/Slc serum triglyceride level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood triglyceride amount male 126 days 6 102.25 mg/dl 25.98 63.64 serum triglyceride analysis 0.0 0 101917 2642
SS.ZUC-Leprfa+/+/Slc serum aspartate aminotransferase activity level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood aspartate transaminase amount male 126 days 6 57.0 U/l 1.52 3.72 automated blood analysis 0.0 0 101927 2642
SS.ZUC-Leprfa+/+/Slc creatinine clearance to body weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. glomerular filtration trait male 126 days 6 0.91 ml/min/100g 0.06 0.15 urine creatinine analysis 0.0 0 101939 2642
SS.ZUC-Leprfa+/+/Slc creatinine clearance to total kidney weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. glomerular filtration trait male 126 days 6 1.25 ml/min/g 0.12 0.29 urine creatinine analysis 0.0 0 101937 2642
SS.ZUC-Leprfa+/+/Slc ejection fraction everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. cardiac output trait male 91 days 10 72.2 % 2.34 7.4 echocardiography 0.0 0 101810 2641
SS.ZUC-Leprfa+/+/Slc blood high density lipoprotein cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood HDL cholesterol amount male 91 days 10 22.5 mg/dl 2.27 7.18 blood cholesterol analysis 0.0 0 101842 2641
SS.ZUC-Leprfa+/+/Slc blood aspartate aminotransferase activity level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood aspartate transaminase amount male 91 days 8 48.5 U/l 0.5 1.41 automated blood analysis 0.0 0 101857 2641
SS.ZUC-Leprfa+/+/Slc serum urea nitrogen level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood urea nitrogen amount male 91 days 8 24.25 mg/dl 0.69 1.95 serum urea nitrogen analysis 0.0 0 101865 2641
SS.ZUC-Leprfa+/+/Slc serum urea nitrogen level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood urea nitrogen amount male 91 days 10 23.55 mg/dl 0.85 2.69 serum urea nitrogen analysis 0.0 0 101866 2641
SS.ZUC-Leprfa+/+/Slc creatinine clearance to body weight ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. glomerular filtration trait male 91 days 8 0.43 ml/min/100g 0.03 0.08 serum creatinine analysis 0.0 0 101877 2641
SS.ZUC-Leprfa+/+/Slc heart left ventricle weight to right ventricle weight ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart left ventricle mass male 126 days 6 4.21 null 0.05 0.12 post excision weight measurement 0.0 0 lv/rv 101897 2642
SS.ZUC-Leprfa+/+/Slc time constant of left ventricular pressure decay everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 10 29.01 ms 2.59 8.19 echocardiography 0.0 0 101826 2641
SS.ZUC-Leprfa+/+/Slc blood total cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood cholesterol amount male 91 days 10 11.83 mg/dl 8.11 25.65 blood cholesterol analysis 0.0 0 101838 2641
SS.ZUC-Leprfa+/+/Slc blood low density lipoprotein cholesterol level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood LDL cholesterol amount male 91 days 10 24.0 mg/dl 0.94 2.97 blood cholesterol analysis 0.0 0 101846 2641
SS.ZUC-Leprfa+/+/Slc blood alanine aminotransferase activity level everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood alanine transaminase amount male 91 days 10 25.5 U/l 1.15 3.64 automated blood analysis 0.0 0 101862 2641
SS.ZUC-Leprfa+/+/Slc tibia straight segment length control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. tibia length male 126 days 6 40.27 mm 0.24 0.59 body measuring method 0.0 0 101887 2642
SS.ZUC-Leprfa+/+/Slc heart weight to tibia length ratio control condition Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. heart mass male 126 days 6 0.33 g/cm 0.01 0.04 post excision weight measurement 0.0 0 101893 2642
SS.ZUC-Leprfa+/+/Slc retroperitoneal fat pad weight to tibia length ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. retroperitoneal fat pad mass female 91 days 12 49.0 mg/mm 3.0 10.39 post excision weight measurement 0.0 ovariectomy 42 days vf/tl 101700 2622
SS.ZUC-Leprfa+/+/Slc myocardial performance index bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 12 0.57 null 0.03 0.1 echocardiography 0.0 ovariectomy 42 days 101740 2622
SS.ZUC-Leprfa+/+/Slc blood total cholesterol level control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood cholesterol amount male 91 days 8 68.0 mg/dl 2.0 5.66 blood cholesterol analysis 0.0 0 101837 2641
SS.ZUC-Leprfa+/+/Slc serum insulin level fasting (for 16 hours) Hattori T, et al., Nutr Diabetes. 2011 Jan 31;1:e1. doi: 10.1038/nutd.2010.1. blood insulin amount male 126 days 6 0.0 mg/dl 0.0 0.0 enzyme linked immunosorbent assay 0.0 0 101915 2642